Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Costs and economics

Topic: Risk, prevention and care in population studies

Plain-language summary

Using a nationally representative survey of older Americans with in-home cognitive testing, researchers estimated that dementia cost the US between $157 billion and $215 billion in 2010, depending on how unpaid family caregiving time is valued. That made dementia more expensive nationally than heart disease or cancer. Nursing home care and paid or unpaid home care together made up 75-84% of the total cost.

What this study adds

Evidence grade: High

This is a follow-up (cohort) study of 856 participants. Dementia cost the US between $157 billion and $215 billion in 2010, making it more expensive nationally than heart disease or cancer. Its stated limit: Cost estimates were highly sensitive to the method used to monetarily value unpaid family caregiving time, and the core dementia diagnosis relied on a relatively small clinically assessed subsample (n=856) statistically imputed to the larger survey population.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013). Monetary Costs of Dementia in the United States. New England Journal of Medicine. https://doi.org/10.1056/nejmsa1204629

Vancouver

Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary Costs of Dementia in the United States. New England Journal of Medicine. 2013. doi:10.1056/nejmsa1204629. PMID: 23550670.

BibTeX

@article{hurd2013-6ad13be5,
  author  = {Hurd, M. D. and Martorell, P. and Delavande, A. and Mullen, K. J. and Langa, K. M.},
  title   = {{Monetary Costs of Dementia in the United States}},
  journal = {New England Journal of Medicine},
  year    = {2013},
  doi     = {10.1056/nejmsa1204629},
  pmid    = {23550670},
  url     = {https://doi.org/10.1056/nejmsa1204629}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Dementia cost the US between $157 billion and $215 billion in 2010, making it more expensive nationally than heart disease or cancer. Nursing home care and paid or unpaid home care together made up 75-84% of the total cost.

Study details

Limitations

Cost estimates were highly sensitive to the method used to monetarily value unpaid family caregiving time, and the core dementia diagnosis relied on a relatively small clinically assessed subsample (n=856) statistically imputed to the larger survey population.

How this study scored 69/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record left out, no data; Study design 7 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read left out, no data. 43 of the 62 points it could be judged on, which is 69 of 100. Total 69 of 100.43 of the 62 points we could judge = 69 of 100

Published in a top-tier journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 43 of the 62 points we could judge it on, which is 69 out of 100.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (New England Journal of Medicine)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 7 / 12 A cohort study following people over time
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2013 — within 20 year(s) of the newest study here
Sample size 2 / 4 856 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 23550670)
Free to read — / 2 Access not recorded — left out of this score
Points 43 / 62 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 43 of the 62 points we could judge it on is 69 out of 100.
Total 69 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

103 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Costs and economics from nearby years

Also tagged “prevalence”

1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Costs and economics

See all studies in Costs and economics →